Trials / Completed
CompletedNCT03243331
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Kathy Miller · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gedatolisib | Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment. |
| DRUG | PTK7-ADC | PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment. |
Timeline
- Start date
- 2018-01-19
- Primary completion
- 2020-05-27
- Completion
- 2020-05-27
- First posted
- 2017-08-09
- Last updated
- 2021-01-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03243331. Inclusion in this directory is not an endorsement.